New Products Help Keep Mylan’s Third-Quarter Results on Track
We don’t anticipate any changes to our fair value estimate or no-moat rating for Mylan as the company’s third-quarter results keep it on track with our year-end expectations. Management reaffirmed its year-end outlook.Mylan’s business continues to face a number of challenges in its U.S. generics business, EpiPen franchise, and regulatory issues at its Morgantown facility, but its international operations and focus on complex products—such as generic Copaxone and biosimilar versions of Neulasta ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.